Novavax, Inc. (NASDAQ: NVAX) is having a relatively strong start to the trading session this morning, and for good reason. The company announced that a peer reviewed journal has published data surrounding the company’s flagship clinical candidate. Of course, the news proved to be positive, leading to excitement among investors and sending the stock upward. Today, we’ll talk about:
- The publication of data;
- what we’re seeing from NVAX as a result;
- and what we’ll be watching for with regard to the stock ahead.
NVAX Announces Publication Of Data
As mentioned above, Novavax is having a relatively strong start to the trading session this morning after the company announced that its data has been published in a peer reviewed journal. In a press release issued after-hours yesterday, the company announced that The New England Jouranl of Medicine has published a peer-reviewed letter to the editor surrounding NanoFlu. In particular, the letter outlined the NVAX Phase 1/2 clinical trial in older adults. The trial compared Matrix-M(TM) adjuvent nanoparticle seasonal influenza vaccine candidate (NanoFlu) to the leading licensed egg-based, high-dose influenza vaccine. To read the review, click here. In a statement, Stanley C. Erck, President and CEO at NVAX, had the following to offer:
We are pleased to be able to share the detailed data from the NanoFlu Phase 1/2 clinical trial with the broader scientific community… The low effectiveness of seasonal influenza vaccines, and in particular the A(H3N2) component of the vaccine, during the 2017-2018 season emphasizes the need for a more effective vaccine. Our non-egg-based, recombinant nanoparticle vaccine, when coupled with Matrix-M, potentially offers broader protection against rapidly evolving drift strain variants. We believe this addresses important public health challenges caused by influenza and offers a significant advantage over current influenza vaccines.
Recently, Novavax reported top-line results from the Phase 1/2 trial, a trial that through positive results, validated the company’s work on NanoFlu. During the study, HAI immune responses were 28% to 64% greater against the homologous and four generations of drifted wild type A(H3N2) influenza strains. In a statement, Dr. Vivek Shinde, Executive Director of Clinical Development at NVAX, had the following to offer:
These results showcase the potential benefit NanoFlu could have for older adults, a population challenged by poor immune responses. This population faces an urgent unmet medical need for a more effective flu vaccine, as highlighted by the severe flu season of 2017-2018… We look forward to advancing this vaccine into the planned Phase 2 clinical trial of quadrivalent NanoFlu in the third quarter of 2018.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news causes moves. In the case of Novavax, the news proved to be overwhelmingly positive. With the publication, yet another point of validation is being offered with regard to the company’s work with NanoFlu. So, it comes as no surprise to see that excited investors are pushing the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:25), NVAX is trading at $1.66 per share after a gain of $0.05 per share or 3.11% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the story surrounding NanoFlu as the product seems to be showing positive results, leading to strong interest from the medical community. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!